生物靶向抑制剂在治疗眼底新生血管中的研究进展  

Research advances on the treatments of fundus neovascularization by bio-targeted inhibitor

作　　者：刘梓煜 刘大川[1] LIU Ziyu;LIU Dachuan(Department of Surgery,Xuanwu Hospital,Capital University of Medical Sciences,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院眼科,北京市100053

出　　处：《眼科新进展》2020年第6期593-596,共4页Recent Advances in Ophthalmology

摘　　要：眼底新生血管是常见的致盲原因,近年来对新生血管抑制剂进行了多方面研究,生物靶向抑制剂成为研究热点。本文从血管内皮生长因子抑制剂、Apelin/APJ通路相关抑制剂和配体组学技术这三方面在抗新生血管中的应用进行综述,使眼科医师对该领域目前研究现状有所了解。Fundus neovascularization is a common blinding ophthalmopathy.In recent years,experts have carried out a variety of researches on neovascularization inhibitors,which bio-targeted inhibitors have become a research focus.This article reviews the application of vascular endothelial growth factor inhibitors,Apelin/APJ pathway related inhibitors and ligandomics technologies in anti-neovascularization,so that we can have an understanding of the current situation.

关 键 词：眼底新生血管 血管内皮生长因子 APELIN 配体组学 

分 类 号：R774.1[医药卫生—眼科]